Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Quantitative and Qualitative Antibody Responses to Streptococcus Pneumoniae and Haemophilus Influenzae Type b Conjugate Vaccines Amongst HIV-1-Exposed-Infected Children That Are Receiving Vs. Those Not Receiving Antiretroviral Therapy, as Well as Among HIV-1-Exposed-Uninfected Children and HIV-1-Unexposed-Uninfected Children

Next Previous
Trial Profile

Evaluation of Quantitative and Qualitative Antibody Responses to Streptococcus Pneumoniae and Haemophilus Influenzae Type b Conjugate Vaccines Amongst HIV-1-Exposed-Infected Children That Are Receiving Vs. Those Not Receiving Antiretroviral Therapy, as Well as Among HIV-1-Exposed-Uninfected Children and HIV-1-Unexposed-Uninfected Children

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pneumococcal 7-valent CRM197 vaccine conjugate (Primary)
  • Indications Haemophilus infections; HIV-1 infections; Pneumococcal infections
  • Focus Pharmacodynamics
  • Acronyms CIPRA Project-4; CIPRA-SA Project-4; CIPRA-SA-4; CIPRA-ZA Project-4; CIPRA-ZA-4

    • Most Recent Events

    • 15 Feb 2020 Results (n=579) assessing effect of HIV-exposure and timing of antiretroviral treatment initiation in children living with HIV on antibody persistence and memory responses to Haemophilus influenzae type b and pneumococcal polysaccharide-protein conjugate vaccines from two clinical trials: NCT00099658 and NCT00102960 were published in the Vaccine
    • 23 Dec 2010 Planned end date changed from 1 May 2010 to 1 Jun 2014 as reported by ClinicalTrials.gov.
    • 22 Jul 2009 Interim results reported at the 5th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top